{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:55:20Z","timestamp":1783018520296,"version":"3.54.6"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003787","name":"Natural Science Foundation of Hebei Province","doi-asserted-by":"publisher","award":["H2021206167"],"award-info":[{"award-number":["H2021206167"]}],"id":[{"id":"10.13039\/501100003787","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>This study aimed to evaluate the influence of pre-transplant spleen volume on the prognosis of patients with acute myeloid leukemia (AML) undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We evaluated 58 patients diagnosed with AML and who have undergone first allogeneic stem cell transplant at the Department of Hematology, Second Hospital of Hebei Medical University from 2017 to 2022. All patients were consecutively evaluated. Patients with AML evolving from myeloproliferative neoplasms (MPN) or secondary AML were excluded. Only\n                      <jats:italic>de novo<\/jats:italic>\n                      AML patients were included. The median follow-up time was 24 months, and the patients were categorized into non-enlarged spleen volume (NLSV) and large spleen volume (LSV) groups based on the spleen volume ranges of 120 normal individuals. A retrospective analysis was performed to evaluate the impact of spleen volume on post-allo-HSCT outcomes, including the incidence of infection, graft-versus-host disease (GVHD), relapse, overall survival (OS), and non-relapse mortality (NRM). Log-rank test was employed to compare survival curves, and a multivariable Cox regression model was utilized to assess spleen volume as a prognostic factor for long-term survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      According to the survival curve, the LSV group exhibited lower OS compared to the NLSV group (\n                      <jats:italic>P<\/jats:italic>\n                      =0.034), along with higher cumulative NRM (\n                      <jats:italic>P<\/jats:italic>\n                      =0.049) and lower relapse-free survival (\n                      <jats:italic>P<\/jats:italic>\n                      =0.023). No significant differences were observed in disease relapse, granulocyte engraftment, CMV infection, or GVHD incidence. The multivariable regression model confirmed spleen volume as a significant risk factor for OS, with cytomegalovirus (CMV) infection also influencing OS and NRM.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Pre-transplant splenomegaly is independently associated with poor prognosis in AML patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2025.1675328","type":"journal-article","created":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T05:18:25Z","timestamp":1771305505000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Effect of pretransplant spleen volume on the prognosis of acute myeloid leukemia treated with allogeneic hematopoietic stem cell transplantation"],"prefix":"10.3389","volume":"16","author":[{"given":"Weiwei","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Hematology and Hematology Key Institute, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bingjie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematology Key Institute, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihou","family":"Pang","sequence":"additional","affiliation":[{"name":"Department of Function, the Second Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lixia","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Imaging, the Second Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fuxu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematology Key Institute, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematology Key Institute, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Hematology Key Institute, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-021-02662-1","article-title":"Immunotherapy in AML: a brief review on emerging strategies","volume":"23","author":"Moeinafshar","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"B2","volume-title":"Cancer stat facts: leukemia \u2014 acute myeloid leukemia (AML)","year":"2025"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.33458","article-title":"De novo acute myeloid leukemia: a population-based study of outcome in the United States based on the Surveillance, Epidemiology, and End Results (SEER) database, 1980 to 2017","volume":"127","author":"Sasaki","year":"2021","journal-title":"Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16suppl.6543","article-title":"Improved overall survival in acute myeloid leukemia over the last 15 years","volume":"42","author":"Dhakal","year":"2024","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23795","article-title":"Gemtuzumab ozogamicin with fludarabine, cytarabine, and granulocyte colony stimulating factor (FLAG-GO) as front-line regimen in patients with core binding factor acute myelogenous leukemia","volume":"89","author":"Borthakur","year":"2014","journal-title":"Am J Hematol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1182\/blood-2019-126014","article-title":"Fludarabine, Cytarabine, G-CSF and Gemtuzumab Ozogamicin (FLAG-GO) regimen results in better molecular response and relapse-free survival in core binding factor acute myeloid leukemia than FLAG and Idarubicin (FLAG Ida)","volume":"134","author":"Borthakur","year":"2019","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.4310","article-title":"Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial","volume":"29","author":"Burnett","year":"2011","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and post consolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukemia: a meta-analysis of individual patient data from randomized controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.18.6130","article-title":"Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin","volume":"27","author":"Ravandi","year":"2009","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-09-736686","article-title":"Long-term outcome of acute promyelocytic leukemia treated with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab","volume":"129","author":"Abaza","year":"2017","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1982","article-title":"Improved outcomes with retinoic acid and arsenic trioxide compared with retinoic acid and chemotherapy in non-high-risk acute promyelocytic leukemia: final results of the randomized Italian-German APL0406 trial","volume":"35","author":"Platzbecker","year":"2017","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00193-X","article-title":"Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukemia in all risk groups (AML17): results of a randomized, controlled, phase 3 trial","volume":"16","author":"Burnett","year":"2015","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"Arber","year":"2022","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00330-1","article-title":"Splenomegaly in patients with primary or secondary myelofibrosis who are candidates for allogeneic hematopoietic cell transplantation: a Position Paper on behalf of the Chronic Malignancies Working Party of the EBMT","volume":"10","author":"Polverelli","year":"2023","journal-title":"Lancet Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.637512","article-title":"Allogeneic hemopoietic stem cell transplantation for myelofibrosis: 2021","volume":"12","author":"Bacigalupo","year":"2021","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1002\/ajh.26020","article-title":"Impact of\u00a0spleen size and splenectomy on outcomes of allogeneic hematopoietic cell\u00a0transplantation for myelofibrosis: A retrospective analysis by the chronic Malignancies working party on behalf of European society for blood and marrow transplantation (EBMT)","volume":"96","author":"Polverelli","year":"2021","journal-title":"Am J Hematol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s10020-025-01085-w","article-title":"Single\u00a0cell RNA sequencing improves the next generation of approaches to AML treatment: challenges and perspectives","volume":"31","author":"Khosroabadi","year":"2025","journal-title":"Mol Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00475","article-title":"Immune biology of acute myeloid leukemia: implications for immunotherapy","volume":"39","author":"Khaldoyanidi","year":"2021","journal-title":"J Clin Oncol"},{"key":"B21","article-title":"Acute myeloid leukemia","volume-title":"StatPearls","author":"Vakiti","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10030436","article-title":"Acute myeloid leukemia evolving from myeloproliferative neoplasms: many sides of a challenging disease","volume":"10","author":"Mannelli","year":"2021","journal-title":"J Clin Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ymthe.2023.01.030","article-title":"Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia","volume":"31","author":"Pasupuleti","year":"2023","journal-title":"Mol Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023021218","article-title":"How I treat transplant-eligible patients with myelofibrosis","volume":"142","author":"Kr\u00f6ger","year":"2023","journal-title":"Blood"},{"key":"B25","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/ajh.27660","article-title":"Allogeneic stem cell transplant for myelofibrosis and myelodysplastic syndromes: A contemporary review","author":"Gagelmann","year":"2025","journal-title":"Am J Hematol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05353-9","article-title":"Pretransplant spleen volume and outcome after hematopoietic stem cell transplantation (HSCT) in patients with acute myeloid leukemia (AML)","volume":"102","author":"Pohlmann","year":"2023","journal-title":"Ann Hematol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2022.101035","article-title":"Haploidentical transplants with a G-CSF\/ATG-based protocol: Experience from China","volume":"62","author":"Xu","year":"2023","journal-title":"Blood Rev"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.retram.2025.103501","article-title":"A comparison of porcine anti-human T lymphocyte immunoglobulin, rabbit-ATG for GVHD prophylaxis and without ATG in matched sibling donor transplantation","volume":"73","author":"Zhou","year":"2025","journal-title":"Curr Res Transl Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.04.036","article-title":"et al; Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia","volume":"21","author":"Cheson","year":"2003","journal-title":"J Clin Oncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"13402","DOI":"10.1038\/s41598-025-98059-z","article-title":"Maintenance therapy with azacitidine for patients with myeloid Malignancies after allogeneic hema topoietic stem cell transplantation","volume":"15","author":"Lu","year":"2025","journal-title":"Sci Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.06.029","article-title":"Prophylactic or preemptive low-dose azacitidine and donor lymphocyte infusion to prevent disease relapse following allogeneic transplantation in patients with high-risk acute myelogenous leukemia or myelodysplastic syndrome","volume":"27","author":"Guillaume","year":"2021","journal-title":"Transpl Cell Ther"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.4236\/fmar.2014.23012","article-title":"Study of volume, weight and size of normal pancreas, spleen and kidney in adults autopsies","volume":"2","author":"Caglar","year":"2014","journal-title":"Forensic Med Anat Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.5461","article-title":"Sex differences in adults with acute myeloid leukemia and the impact of sex on overall survival","volume":"12","author":"Stabellini","year":"2023","journal-title":"Cancer Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.06.026","article-title":"Relative impact of HLA matching and non-HLA donor characteristics on outcomes of allogeneic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome","volume":"24","author":"Ayuk","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e572","DOI":"10.1097\/HS9.0000000000000572","article-title":"Treatment for relapsed\/refractory acute myeloid leukemia","volume":"5","author":"Thol","year":"2021","journal-title":"Hemasphere"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2020.04.008","article-title":"Impact of splenomegaly on outcomes of allogeneic hematopoietic stem cell transplantation in patients with chronic myelomonocytic leukemia","volume":"41","author":"Zhao","year":"2020","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1097\/BS9.0000000000000121","article-title":"Risk factors for CMV infection within 100 days post transplantation in patients with acute leukemia","volume":"4","author":"Chen","year":"2022","journal-title":"Blood Sci"},{"key":"B38","doi-asserted-by":"publisher","first-page":"697.e1","DOI":"10.1016\/j.jtct.2023.08.009","article-title":"Choosing between older matched sibling donor and younger matched unrelated donor in allogeneic hematopoietic cell transplantation: comparison of clinical outcomes in acute myeloid leukemia and myelodysplastic syndrome","volume":"29","author":"Pereira","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2022.05.009","article-title":"Advantages of peripheral blood stem cells from unrelated donors versus bone marrow transplants in outcomes of adult acute myeloid leukemia patients","volume":"24","author":"Jo","year":"2022","journal-title":"Cytotherapy"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-023-02095-0","article-title":"The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP\/EBMT","volume":"58","author":"Nagler","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"B41","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-021-00240-3","article-title":"Roles of the intestinal microbiota and microbial metabolites in acute GVHD","volume":"10","author":"Lin","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/16078454.2021.1872957","article-title":"Impact of pre-transplant use of antibiotics on the graft-versus-host disease in adult patients with hematological Malignancies","volume":"26","author":"Lee","year":"2021","journal-title":"Hematology"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2022.2042064","article-title":"Primary graft failure following allogeneic hematopoietic stem cell transplantation: risk factors, treatment and outcomes","volume":"27","author":"Chen","year":"2022","journal-title":"Hematology"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1080\/09537104.2023.2229905","article-title":"Exploration of risk factors of platelet transfusion refractoriness and its impact on the prognosis of hematopoietic stem cell transplantation: a retrospective study of patients with hematological diseases","volume":"34","author":"Song","year":"2023","journal-title":"Platelets"},{"key":"B45","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.cell.2020.01.022","article-title":"Tissue determinants of human NK cell development, function, and residence","volume":"180","author":"Dogra","year":"2020","journal-title":"Cell"}],"updated-by":[{"DOI":"10.3389\/fimmu.2026.1889158","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000}}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1675328\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T17:46:21Z","timestamp":1783014381000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1675328\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,17]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2025.1675328"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1675328","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,17]]},"article-number":"1675328"}}